Galidesivir for COVID-19
Galidesivir has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652 ,
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279 ,
Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736 ,
A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2 ,
Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432 ,
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.